41/100BHumana stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Humana is 473.74, 7.9% above the current price of 439.05. Their targets range from 300.00 to 596.00.
Of the 20 firms that rated Humana in the past 12 months, 12 rate it buy or strong buy, 7 hold and 1 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 300.00 to 596.00, with an average of 473.74.
| Buy | 12 | |
| Hold | 7 | |
| Sell | 1 |
12-month price target
| Highest target | 596.00 |
| Average target | 473.74 |
| Lowest target | 300.00 |
| Current price | 439.05 |
Humana price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Humana price target and rating?
How analysts rate Humana, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12 of 20 firms rate it buy now, against 7 of 17 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Humana analyst upgrades, downgrades and price targets
The latest rating change came on 12 October 2026, when Raymond James upgraded Humana from Market Perform to Outperform. Its price target is 520.00, from 460.00. The most recent new target came from Piper Sandler on 9 November 2026: 526.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 9 Nov 2026 | Piper Sandler Jessica Tassan | Reiterated · Overweight | 463.00 → 526.00 | +13.6% | 433.31 |
| 6 Nov 2026 | Jefferies David Windley | — | 410.00 → 420.00 | +2.4% | 421.47 |
| 13 Oct 2026 | Mizuho Securities | Reiterated · Outperform | 390.00 → 495.00 | +26.9% | 433.50 |
| 12 Oct 2026 | Oppenheimer | Reiterated · Outperform | 475.00 → 525.00 | +10.5% | 430.16 |
| 12 Oct 2026 | UBS | Reiterated · Neutral | 596.00 → 495.00 | -16.9% | 431.50 |
| 12 Oct 2026 | Truist Financial David MacDonald | Reiterated · Hold | 415.00 → 475.00 | +14.5% | 431.03 |
| 12 Oct 2026 | Raymond James | Upgraded · Market Perform → Outperform | 460.00 → 520.00 | +13.0% | 431.03 |
| 9 Oct 2026 | Oppenheimer | Reiterated · Outperform | 405.00 → 475.00 | +17.3% | 387.12 |
| 9 Oct 2026 | Barclays | Reiterated · Overweight | 515.00 → 582.00 | +13.0% | 387.12 |
| 9 Oct 2026 | UBS | — | 405.00 → 596.00 | +47.2% | 387.12 |
| 9 Oct 2026 | Robert W. Baird Michael Ha | — | 390.00 → 596.00 | +52.8% | 387.12 |
| 9 Oct 2026 | Baird | Upgraded · Neutral → Outperform | — | — | — |
| 7 Oct 2026 | Raymond James Sarah James | — | 300.00 → 460.00 | +53.3% | 404.28 |
| 7 Oct 2026 | Cantor Fitzgerald | Upgraded · Neutral → Overweight | — | — | — |
| 25 Sept 2026 | Barclays | Upgraded · Equal Weight → Overweight | 407.00 → 515.00 | +26.5% | 379.96 |
| 24 Aug 2026 | Wolfe Research Justin Lake | — | 450.00 | — | 378.87 |
| 5 Aug 2026 | Morgan Stanley | Upgraded · Underweight → Equal Weight | — | — | — |
| 4 Aug 2026 | Morgan Stanley | — | 249.00 → 370.00 | +48.6% | 362.16 |
| 31 Jul 2026 | Barclays | Reiterated · Equal Weight | 344.00 → 407.00 | +18.3% | 366.61 |
| 30 Jul 2026 | Piper Sandler | — | 254.00 → 463.00 | +82.3% | 369.62 |
| 30 Jul 2026 | UBS | Reiterated · Neutral | 320.00 → 405.00 | +26.6% | 367.84 |
| 30 Jul 2026 | Oppenheimer Michael Wiederhorn | — | 260.00 → 405.00 | +55.8% | 367.16 |
| 30 Jul 2026 | Robert W. Baird | — | 390.00 | — | 365.89 |
| 30 Jul 2026 | Guggenheim | Reiterated · Buy | 269.00 → 471.00 | +75.1% | 365.89 |
| 30 Jul 2026 | Leerink Partners | — | 513.00 | — | 365.89 |
| 30 Jul 2026 | Evercore ISI Group | Upgraded · In Line → Outperform | — | — | — |
| 30 Jul 2026 | Raymond James | Downgraded · Outperform → Market Perform | — | — | — |
| 29 Jul 2026 | Evercore ISI | — | 195.00 → 480.00 | +146.2% | 365.45 |
| 20 Jul 2026 | Jefferies | — | 313.00 → 410.00 | +31.0% | 398.25 |
| 14 Jul 2026 | Truist Financial David MacDonald | Reiterated · Hold | 320.00 → 415.00 | +29.7% | 406.00 |
| 13 Jul 2026 | Wells Fargo Stephen Baxter | Upgraded · Equal Weight → Overweight | 206.00 → 502.00 | +143.7% | 392.22 |
| 9 Jul 2026 | RBC Capital | Reiterated · Sector Perform | 246.00 → 415.00 | +68.7% | 401.34 |
| 7 Jul 2026 | Cantor Fitzgerald | Reiterated · Neutral | 300.00 | — | 392.86 |
| 7 Jul 2026 | Raymond James Sarah James | — | 260.00 → 300.00 | +15.4% | 392.86 |
| 8 Jun 2026 | Mizuho Securities | Reiterated · Outperform | 335.00 → 390.00 | +16.4% | 350.08 |
| 4 Jun 2026 | Morgan Stanley | Reiterated · Underweight | 217.00 → 249.00 | +14.7% | 327.54 |
| 3 Jun 2026 | Bernstein | — | 344.00 → 425.00 | +23.5% | 320.88 |
| 1 Jun 2026 | Truist Financial David MacDonald | Reiterated · Hold | 270.00 → 320.00 | +18.5% | 305.42 |
| 26 May 2026 | Barclays | Reiterated · Equal Weight | 180.00 → 344.00 | +91.1% | 300.86 |
| 22 May 2026 | UBS | Reiterated · Neutral | 262.00 → 320.00 | +22.1% | 303.68 |
| 20 May 2026 | Mizuho Securities | Reiterated · Outperform | 258.00 → 335.00 | +29.8% | 310.55 |
| 20 May 2026 | Deutsche Bank | Upgraded · Hold → Buy | 235.00 → 441.00 | +87.7% | 310.55 |
| 15 May 2026 | Morgan Stanley Erin Wright | Reiterated · Underweight | 146.00 → 217.00 | +48.6% | 301.35 |
| 13 May 2026 | Piper Sandler | Reiterated · Neutral | 254.00 | — | 295.35 |
| 1 May 2026 | Raymond James | — | 201.00 → 260.00 | +29.4% | 236.44 |
| 30 Apr 2026 | RBC Capital Ben Hendrix | Reiterated · Sector Perform | 189.00 → 246.00 | +30.2% | 240.92 |
| 30 Apr 2026 | Deutsche Bank | — | 180.00 → 235.00 | +30.6% | 241.10 |
| 30 Apr 2026 | Oppenheimer | — | 250.00 → 260.00 | +4.0% | 242.68 |
| 30 Apr 2026 | Truist Financial David MacDonald | Reiterated · Hold | 200.00 → 270.00 | +35.0% | 243.12 |
| 30 Apr 2026 | Guggenheim | Reiterated · Buy | 252.00 → 269.00 | +6.7% | 243.12 |
Humana EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Humana's EPS to grow 54.4% a year until 2028. Over the last 5 years it fell 17.2% a year, and over the last 3 years it fell 23.6%.
Analysts expect Humana's revenue to grow 13.3% a year until 2028, about as fast as over the last 5 years (10.9% a year) and the last 3 years (11.7%).
Revenue
EPS
Does Humana beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 15.6% off the result, either way, and their revenue estimate 1.9%, over the last 12 quarters.
- EPS beats
- 91 / 135
- Revenue beats
- 90 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +6.1%
- Since
- March 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 6 Nov 2026 | -1.00 | -0.70 | +30.0% | 40.87B | 41.16B | +0.7% |
| Q2 FY2026 | 29 Jul 2026 | 7.27 | 7.61 | +4.7% | 40.58B | 40.87B | +0.7% |
| Q1 FY2026 | 29 Apr 2026 | 10.24 | 10.31 | +0.7% | 39.37B | 39.65B | +0.7% |
| Q4 FY2025 | 11 Feb 2026 | -4.00 | -3.96 | +1.0% | 32.04B | 32.52B | +1.5% |
| Q3 FY2025 | 5 Nov 2025 | 2.93 | 3.24 | +10.6% | 32.00B | 32.65B | +2.0% |
| Q2 FY2025 | 30 Jul 2025 | 5.92 | 6.27 | +5.9% | 31.87B | 32.39B | +1.6% |
| Q1 FY2025 | 30 Apr 2025 | 10.07 | 11.58 | +15.0% | 32.20B | 32.11B | -0.3% |
| Q4 FY2024 | 11 Feb 2025 | -2.23 | -2.16 | +3.1% | 28.81B | 29.21B | +1.4% |
| Q3 FY2024 | 30 Oct 2024 | 3.40 | 4.16 | +22.4% | 28.68B | 29.40B | +2.5% |
| Q2 FY2024 | 31 Jul 2024 | 5.85 | 6.96 | +19.0% | 28.52B | 29.54B | +3.6% |
| Q1 FY2024 | 24 Apr 2024 | 6.12 | 7.23 | +18.1% | 28.52B | 29.61B | +3.8% |
| Q4 FY2023 | 25 Jan 2024 | -0.07 | -0.11 | -57.1% | 25.54B | 26.46B | +3.6% |
Humana stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Humana's earnings grow at the 28.3% a year analysts expect to FY2028, then 15.0% a year, it would earn about 47.90 a share in FY2030. At the P/E it has traded at over the last five years (20.4 to 42.3) that is 974.95 to 2,026.07 a share, or 1,275.80 at its average P/E of 26.6. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 9.48 | 192.87 | 252.39 | 400.82 |
| FY2027 | 18.53 | 377.10 | 493.47 | 783.68 |
| FY2028 | 36.22 | 737.20 | 964.69 | 1,532.00 |
| FY2029 (extrapolated) | 41.65 | 847.78 | 1,109.39 | 1,761.80 |
| FY2030 (extrapolated) | 47.90 | 974.95 | 1,275.80 | 2,026.07 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (20.4, 26.6, 42.3).
Is Humana stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Humana's P/E of 42.3 is near the top of its 5-year range (14.7 to 43.7, median 21.0). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E. Fair value is not a reliable guide for Humana: its earnings swing (EPS fell 50.1% in FY2024), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 46.3.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 42.30
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 21.04
- Five-year P/E range
- 14.7 – 43.7
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 46.33
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.49
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +7.9%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.